# Serum sST2/ miR-223 as a Dual Biomarker for Disease Activity & Clinical Efficacy of SLIT in HDM-Induced Allergic Rhinitis

> **NCT07436208** · PHASE1 · COMPLETED · sponsor: **Zagazig University** · enrollment: 54 (actual)

## Conditions studied

- HDM-Induced Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** Sublingual Immunotherapy (SLIT) containing HDM extracts

## Key facts

- **NCT ID:** NCT07436208
- **Lead sponsor:** Zagazig University
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-01
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07436208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07436208, "Serum sST2/ miR-223 as a Dual Biomarker for Disease Activity & Clinical Efficacy of SLIT in HDM-Induced Allergic Rhinitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07436208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*